Industry: Flexible & Barrier Packaging (Packaging)
Source: https://www.mordorintelligence.com/industry-reports/pharmaceutical-blister-packaging-market
Scraped Date: 2026-09-17
| Market Metric | Details |
|---|---|
| Base Market Size | USD 24.97 billion |
| Projected Forecast (2031) | USD 24.97 billion |
| Growth Rate (CAGR) | 7.10 % |
| Largest Market Region | N/A |
| Fastest-Growing Region | N/A |
!Major players in Pharmaceutical Blister Packaging industry
!Pharmaceutical Blister Packaging Market Summary
!Pharmaceutical Blister Packaging Market: Market Share by Material, 2025
!Pharmaceutical Blister Packaging Market: Market Share by Application, 2025
!Pharmaceutical Blister Packaging Market CAGR (%), Growth Rate by Region
!Pharmaceutical Blister Packaging Market Concentration
!Icon
!Vijeron Intelligence on Facebook
!Vijeron Intelligence on Pinterest
!Vijeron Intelligence on Instagram
!GPTW
Market OverviewStudy Period | 2020 - 2031 |
Market Size (2026) | USD 24.97 Billion |
Market Size (2031) | USD 35.17 Billion |
Growth Rate (2026 - 2031) | 7.10 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | Asia Pacific |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order
Image © Vijeron Intelligence. Reuse requires attribution under CC BY 4.0.
|
Pharmaceutical Blister Packaging Market Analysis by Vijeron IntelligencePharmaceutical blister packaging market size in 2026 is estimated at USD 24.97 billion, growing from 2025 value of USD 23.31 billion with 2031 projections showing USD 35.17 billion, growing at 7.10% CAGR over 2026-2031. Demand is rising because solid-dose drugs remain the dominant oral therapy, regulators favor unit-dose formats for accuracy, and smart sensors now fit seamlessly into standard blisters. Firms are also working around aluminum price swings by qualifying recyclable high-barrier plastics and by reshoring foil supply. Asia-Pacific is the largest production hub and accounts for more than one-third of global output thanks to competitive labor costs and strong local demand; growth momentum there is reinforced by state incentives for continuous-manufacturing lines and expanding CDMO capacity. Capacity additions in the United States and the European Union signal that global players want network resilience as well as proximity to high-value biologics pipelines. Digital adherence packs launched by Aardex Group and sensor-ready closures from Gerresheimer show how packaging is now part of connected-health strategies, which opens new revenue streams for data analytics services.
Key Report Takeaways* By material, plastic films led with 50.72% revenue share in 2025, while paper and paperboard are expanding at a 9.12% CAGR through 2031.
Market Trends and InsightsDrivers Impact Analysis of Pharmaceutical Blister Packaging Market*Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
Rise in demand for unit-dose adherence packs | +1.2% | North America, EU, expanding globally | Medium term (2-4 years) |
Growing adoption of recyclable high-barrier plastics | +0.8% | EU leading, uptake in North America and Asia-Pacific | Long term (≥ 4 years) |
Expansion of chronic-disease oral therapies | +1.5% | Global, highest therapy growth in Asia-Pacific | Long term (≥ 4 years) |
Aging population boosting OTC solid-dose demand | +1.1% | North America and EU core, emerging in Asia-Pacific | Long term (≥ 4 years) |
Emergence of smart, sensor-enabled blister packs | +0.9% | Early adoption in North America and EU | Medium term (2-4 years) |
Continuous-manufacturing lines with inline blistering | +0.6% | Global pharma hubs | Medium term (2-4 years) |
Source: Vijeron Intelligence |
Competitive Landscape
The pharmaceutical blister packaging market features a moderate level of fragmentation, with a long tail of regional converters operating beside diversified multinationals. Uhlmann, Marchesini, and Körber supply turnkey lines, yet local integrators customize end-of-line coding and aggregation. Patent filings cover child-resistant one-piece packs that eliminate secondary cartons and integrate authentication microtext.
Mergers and acquisitions expand scale and technology portfolios. Jabil moved into healthcare by buying Pharmaceutics International, while Blue Wolf Capital stitched together three facilities to form a mid-tier CDMO. Sustainability remains a differentiator; Aptar’s N-Sorb absorber targets nitrosamine prevention, earning a place in the FDA Emerging Technology Program and enhancing the firm’s credibility with oncology drug sponsors.
Digital convergence spurs collaboration between packaging converters and software firms. Aardex licenses cloud dashboards to blister suppliers so hospitals can track adherence without adding hardware. BD embeds RFID tags in prefillable syringes, signaling similar connectivity will migrate to oral-dose packs. As connected formats scale, data-privacy compliance and cybersecurity become new competitive dimensions.
Pharmaceutical Blister Packaging Industry Leaders* Constantia Flexibles
Image © Vijeron Intelligence. Reuse requires attribution under CC BY 4.0.
This market covers blister packs used to package pharmaceutical products, measured in value terms, and includes the main blister materials and the common forming technologies used to make those packs.
Scope exclusions: We exclude non-blister pharmaceutical packaging formats (such as bottles, sachets, and vials) and secondary packaging items unless they are integral to the blister pack itself.
The pharmaceutical blister packaging market size reached USD 24.97 billion in 2026 and is projected to hit USD 35.17 billion by 2031.
Plastic films, mainly PVC-based structures, commanded 50.72% revenue share in 2025.
They dissolve quickly without water, improve patient compliance, and post the fastest 10.79% CAGR, prompting specialized high-barrier blister designs.
EU rules require all packs sold after 2030 to be recyclable, so converters now use PCR plastics and ultra-thin barrier coatings to meet future compliance.
CDMOs show a 9.05% CAGR because pharmaceutical firms outsource packaging to access advanced blister lines and serialization without large capital expenditure.
Sensor-enabled packs record each dose removal and transmit data to care teams, which can improve adherence and support value-based reimbursement models.